Melanoma CDSS: Enhancing diagnosis and prognosis of skin cancer

Client: Biocruces Bizkaia
Date: 2024
Location: Basque Country
Technologies used: Artificial intelligence
Partners: Tecnalia, Biocruces and Ayesa

Challenge
Solution
Benefits

Challenge

One of the goals of the Biocruces Bizkaia, the research and innovation institute of the National Basque Health System in Biscay, is to promote research in areas such as biomedicine, epidemiology, public health and healthcare services, as well as foster translational research, i.e. the transfer of scientific knowledge to clinical settings.

One of its main areas of research is cancer, specifically melanoma, a neoplastic disease with a poor prognosis that is on the rise.

Solution

Ayesa has developed a virtual platform called Melanoma CDSS to assist dermatologists and oncologists in diagnosing melanoma and enhancing patient prognosis. The platform identifies patients at risk of developing metastasis and recommends targeted adjuvant therapies to prevent its progression. This innovative approach is set to significantly improve progression-free survival rates for patients.

Benefits

The solution is poised to generate a wealth of additional data on melanoma patients, building on the existing data collected over the project’s three-year duration. As an intelligent system, it will also have the capability to learn during the clinical validation phase.

Currently, a range of indicators is being analyzed, including age, sex, family history, biomarkers, and dermatoscopic images. These factors will be incorporated into the final version of the Melanoma CDSS, enhancing its effectiveness and accuracy

“AI is a valuable tool that can help improve the prognosis of patients with melanoma, a disease that has seen a rapidly increasing rate of diagnosis over recent years”.

Ayesa